New cancer biotech emerges from Stanford research, with help of Nobel laureate Carolyn Bertozzi

A new solid tumor biotech based on research out of Stanford University is targeting the red-hot fields of cancer immunotherapy and antibody-drug conjugates.

TwoStep Therapeutics unveiled itself on Tuesday morning, and its bold bets — changing the immunotherapy field and bringing a new flavor to pharma’s en vogue oncology modality — are advised by several high-profile entrepreneurs and researchers. They include Nobel laureate Carolyn Bertozzi and Jennifer Cochran, Stanford’s senior associate vice provost for research. Another TwoStep co-founder is Stanford professor Ronald Levy, who helped develop the lymphoma treatment rituximab.

With a $6.5 million seed round to begin, the Palo Alto upstart will work on choosing its lead program and raising a Series A next year to fund IND-enabling and Phase 1b studies, CEO Caitlyn Miller said in an exclusive interview with Endpoints News.

Miller worked with Bertozzi and Cochran during her PhD and…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks